objeCtives: To systematically review the currently available clinical and costeffectiveness evidence of non-pegylated liposomal doxorubicin (NPLD) for non-Hodgkin lymphoma (nHL). The hypothesis under verification was that the administration of NPLD lowers the cardiotoxicity typical for conventional anthracyclines while being able to sustain the clinical effect of treatment. Methods: A systematic literature search was conducted for clinical and cost-effectiveness data for the nHL population treated with NPLD, using the main medical databases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries were searched, reference lists of included studies and reviews were screened for missed studies. Searches took place in September 2012. Results: The review generated 9 one-arm clinical trials and 1 retrospective study which met the inclusion criteria. One comparative parallel trial comparing R-CHOP with R-COMP in the DLBCL population is ongoing, with no results published. Generally, available evidence is poor -studies identified are characterized by many limitations, i.e.: small and heterogeneous study populations, relatively short observation period, not always specified inclusion and exclusion criteria, diversified treatment regimens (with R-CHOP dominating), shortened or/and presented selectively safety data. The majority of studies was performed in the DLBCL population. Cumulative interpretation of data was hindered due to essential differences in between trials. Lowering of LVEF was observed with a frequency of 0% to 31,7% of cases, while symptomatic lowering of LVEF with the development of chronic ischemic heart disease occurred with the frequency of 0 to 10%. The second most frequent cardiological event observed was arrhythmia. Clinical efficacy focused on surrogate endpoints (radiological responses), defined differently in between trials. No economic evaluations studies were found. ConClusions: There is limited evidence on the effectiveness and safety of NPLD in patients with nHL due to the lack of well-designed and well-reported comparative studies. Further research is needed to explore the hypothesis in question. Wilson T. , Hamerslag L. Costello Medical Consulting Ltd., Cambridge, UK objeCtives: To ascertain whether there were any trends in cancer mortality after hospital admittance and diagnosis that could be linked to recent approval of therapies by the National Institute for Health and Care Excellence (NICE). Methods: Using information provided by Hospital Episode Statistics and the Office of National Statistics, yearly mortality data from both the inpatient and outpatient population between 2007 and 2010 were extracted. An analysis of 30-, 60-, and 90-day mortality following admittance to hospital was undertaken for malignancies which had seen therapies approved by NICE after 2006. Results: Of the 37 cancer therapies assessed by NICE between 2006 and 2010 inclusive, 27 were recommended. Patients with lung cancer were found to experience one of the highest mortality rates overall. Interestingly, lung cancer also saw the largest number of therapies approved between 2006 and 2010 (7), along with a steady decline in the annual 90-day mortality over the three year period (29.6%, 28.4% and 27.1% in 2007-08, 2008-09 and 2009-to chemotherapy. The algorithm was validated against a PSA-based definition of CRPC (at least two PSA increases following castration or new metastases while on hormone therapy). Results: A total of 269 patients met inclusion criteria and had 3 or more PSA measurements. The two methods agreed in 88% of patients; 220 (81.8%) were identified as CRPC by both methods and 17 (6.3%) were identified as not castration resistant by both methods. A statistical comparison of the two methods yielded a Cohen's kappa of 0.4491, indicating moderate agreement. ConClusions: The algorithm was concordant with a PSA-based definition of CRPC and serves as a new tool to identify CRPC patients using claims data. Future validation against a different data source is needed.
PCN207 imPaCT of ReCommeNded PhaRmaCeuTiCals oN CaNCeR moRTaliTy: aNalysis of Real-life daTa

PCN202
iNCReased Risk of CaNCeR iNCideNCe assoCiaTed wiTh RePeaT mediCal imagiNg: desigNiNg BeTTeR CliNiCal TRial PRoToCols Zowall H. , Brewer C. , Deutsch A. Zowall Consulting Inc., Westmount, QC, Canada objeCtives: To assess the potential increase in lifetime attributable risk (LAR) of cancer incidence due to repeated exposure to medical imaging procedures for participants in clinical trials. Methods: Medical imaging in clinical trials has grown exponentially in the last decade. We have developed an individual-based state-transition model to estimate the LAR of radiation-related cancer following a patient's exposure history, and site-specific dose according to age and gender. Monte Carlo simulations to vary effective doses, risk model coefficients, and the period for radiation-related cancer latency were performed. Results: We examined two scenarios in a three year hypothetical clinical trial: minimal exposure describing a subject's radiation exposure as one abdominal CT scan per year; and frequent exposure consisting of five abdominal CT scans per year. For a 30 year old female the LAR of cancer incidence increased from 46 per 100,000 population in the minimal exposure scenario to 229 per 100,000 in the frequent exposure scenario. For a 30 year old male, the risk increased from 36 to 179 per 100,000. At age 30, females had a 30% higher risk than males, however, cancer incidence at ages 50, and 70 were similar for both sexes. At age 50 the LAR of cancer incidence increased from 31 to 151 per 100,000. At age 70 the risk increased from 15 to 71 per 100,000. The LAR of cancer incidence was one third lower in 70 year olds than in 30 year olds, and half the rate of 50 year olds. ConClusions: Although the LAR of cancer incidence of a single exposure seems to be relatively small, clinical trials that involve a comparatively large number of imaging procedures can lead to significantly higher risks. Examinations that deliver relatively high doses of radiation, such as CT, need to be clinically justified.
PCN203 TReNds iN ChemoTheRaPy seTTiNg aNd CosTs fRom 2005 To 2012: a Case sTudy usiNg BevaCizumaB
Foley K. Truven Health Analytics, Cambridge, MA, USA objeCtives: The rising costs of cancer care are a major focus for clinicians, payers and patients. This analysis examines trends in bevacizumab chemotherapy administration and drug reimbursement. Methods: Using the MarketScan © Research Databases, administrations of bevacizumab were identified from 1/1/2005 through 12/31/2012 for patients with commercial or employer-sponsored supplemental Medicare insurance. Bevacizumab claims were excluded if the claim had a diagnosis related to eye disease or the reimbursed amount was < $100. All claims were identified as occurring in an office-based setting (OBS), an outpatient hospital setting (OHS) or other setting. Results: The percent of bevacizumab claims occurring in OHS increased from 6 to 34% among Medicare claims, and from 14 to 42% among commercial claims from 2005 to 2012. Medicare median drug reimbursement was $257 more for OHS than OBS in 2005, increasing to a difference of $3,022 in 2009 and declining to $1,722 in 2011 before narrowing to $165 in 2012. Medicare median reimbursements for chemotherapy administration in OHS were $408 more than OBS in 2005, dropping to a difference of $97 in 2008 and ending at $165 in 2012. Commercial differences in drug reimbursement for OHS and OBS settings continuously increased from $885 in 2005 to $3714 in 2011, declining slightly to $3676 in 2012. Differences in chemotherapy administration reimbursement were $176 more for OHS than OBS in 2005, the difference decreasing to $103 in 2007 and increasing to $236 in 2012. ConClusions: Although the difference in reimbursements to OHS and OBS has decreased over time for Medicare, the differences across settings for commercial insurance increased over time with a slight indication that cost increases are slowing. The higher reimbursements in OHS combined with the shift from OBS to OHS over the past 7 years has implications for the growth in cancer costs over the past decade.
PCN204 Novel maRkeT aCCess models foR CaNCeR dRugs
Aggarwal S. , Kumar S. , Topaloglu H. Novel Health Strategies, Bethesda, MD, USA objeCtives: Cancer drugs are the world's highest selling category of therapeutic products. Due to their premium price and budget impact, several new drug reimbursement models have been implemented worldwide by public and private payers. These models have potential implications for coverage and reimbursement of all branded products. This study reviewed recent cancer drug reimbursement models and developed lessons and implications for future products. Methods: Reviewed cancer drug reimbursement schemes in developed and emerging markets. Interviewed payers and KOLs to develop lessons and implications for future products. Results: Public and private payers worldwide have implemented several new models for cancer drug reimbursement to manage budgets and control costs. In the US, private payers are piloting single source compendia and third party protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has successfully negotiated lower price and discounts for first few cycles of therapy. In Italy, AIFA has implemented registry based patient access for cancer drugs. In India, several manufacturers have implemented novel pricing strategy for first few cycles of therapy. and a combination of tegafur, gimeracil and oteracil. Across these oncology assessments a total of 19 patient subgroups have been evaluated. Eleven subgroups (58%) showed an additional benefit according to the G-BA. Eight subgroups (42%) received the rating "no additional benefit" or "less benefit than comparator". The comparators chosen by G-BA within subgroups vary widely depending on the indication. Key factors for the positive outcome of these assessments were increased overall survival, reduction of symptoms or improved quality of life. Main reasons for the G-BA to attest no additional benefit include inappropriate indirect comparison and lack of adequate patient subgroup analysis. ConClusions: Analysis of HTA reports in oncology shows that while overall survival is a strong end point, also increased quality of life and reduced side-effects can be sufficient to achieve a beneficial outcome (crizotinib: considerable benefit). Importantly, the provided data must be applicable to the German regulations under AMNOG, showing clinical evidence against the specified comparator. The amount of the additional benefit plays an important role in the reimbursement amount negotiations following the definition of the additional benefit by the G-BA.
PCN211 healTh TeChNology assessmeNT: is iT The RighT PieCe foR The JoRdaNiaN healTh CaRe Puzzle?
Al Rabayah A. A. , Jaddoua S. King Hussien Cancer Center, Amman, AL, Jordan objeCtives: To study the pharmaceutical reimbursement/Coverage decision making processes in Jordan to highlight the importance of conducting formalized technology assessments Methods: To review publically available data regarding the reimbursement/Coverage decision making processes in Jordan through searching related organization's websites and publically available regulations. Results: Jordan is characterized with a fragmented health care system. Pharmaceutical registration and pricing are under the responsibility of the JFDA. Furthermore, it is responsible about medication selection for the Rational Drug List (the national formulary). The medication supply chain differs between the public and the private sectors in term of process and out puts. The medication selection process is not governed by criteria and not empowered by an independent review body to support decision making by the national appraisal committee (national P&T). The rational drug list is publically available but without details of the decision or the processes of decision making process. Listing of new medication is wide without indication specification or date of listing. The role of cost-effectiveness is limited and the tender prices are not linked to any type of cost effectiveness analysis ConClusions: The National Agenda, the National health Policy and the National Drug Policy tackled the high health expenditure in Jordan as an essential priority. This challenged is due to the characteristics of the Jordanian health care system that is fragmented with a divided funding system between public and private sectors. A more formalized medication selection processes empowered with drug information services that provide evidence based data and analysis in the form of technology assessment would play a role in decreasing health care expenditures. All of these recommendations should move parallel with improving the level of transparency and patient engagement.
PCN214 ePidemiology foR oNCologiCal dRugs RegaRdiNg The BeNefiT dossieR PRePaRaTioN iN geRmaNy
Kürschner N. , Schmitter S. Pfizer Deutschland GmbH, Berlin, Germany objeCtives: An early benefit assessment of drugs after launch has been implemented since 2011 in Germany. The Institute for Quality and Efficiency in Health Care (IQWiG) assesses the benefit of the drug based on a dossier submitted by the pharmaceutical manufacturer. Based on this assessment and the statements by industry, scientific community and patient organizations the Federal Joint Committee (G-BA) reviews and decides on the extent of the additional benefit. The dossier needs also to contain information about the number of patients treated with the new drug. The objective is to investigate the sources considering the calculation of patient numbers for oncological drugs. Methods: A review of oncological drugs which passed through the benefit assessment was conducted to evaluate which data sources and methods were used to calculate the potential patient number. The results were compared with IQWiG's assessment and the final decision by G-BA, to detect possible methodological difficulties. Results: The data sources regarding German epidemiological data were mainly collected through publicly available sources such as national and local cancer registries. Difficulties occurred with small cancer entities or when specific data regarding patient subpopulations (e.g. through age, tumor stages, ECOG performance status or previous therapies) was needed. The pharmaceutical manufacturer's calculations were often challenged by IQWiG and G-BA without suggesting a precise alternative or more suited data source. ConClusions: The data collection and data availability within the benefit dossier process for oncological drugs is in most cases challenging and the efforts needed should not be underestimated. Authorities, industry and medical community should work on a common solution for a more valid and reliable calculation of the potential patient number in oncology.
PCN215 eCoNomiCal losses due To disaBlemeNTPaReNTs CaRRiNg foR ChildReN wiTh oNCohemaTologiCal diseases
Ganieva D. 1 , Zhukovskaya E. 1 , Spichak I. 2 1 Federal Scientific Centre of Children Hematology, Oncology, Immunologyl, Moskow, Russia, 2 Medical Academy, Chelyabinsk, Russia objeCtives: Socio-economic phenomena, caused by disease of children are reflected primarily in the formation of non-medical costs. Methodology for calculation of nonmedical costs includes a number of parameters, including the cost of lost output by persons caring for children during the treatment period. Methods: The study involved patients from Oncohematological Chelyabinsk Center for Children and Adolescents behalf of prof. V. Gerein been treated in the period from 2008 to 2013. 10, respectively). Similarly, patients admitted to hospital with oesophageal cancer experienced a high 90-day mortality rate, ranging from 22% to 21.9% in 2007-08 and 2009-10, respectively. However, between 2006 and 2010, no therapies were submitted for NICE appraisal for oesophageal cancer, suggesting that there may have been a lack of research interest and potentially explaining why there was no substantial decrease in mortality from 2007, as compared to indications where therapies had been approved, such as lung, colon and breast cancer. ConClusions: The recommendation of therapies and their uptake in the UK may at least partially explain the trends noted in this study, although other factors such as delay in therapy uptake and off-label use may also need to be taken into account.
PCN208
do NiCe evideNCe Review gRouPs (eRg) foCus oN diffeReNT asPeCTs of maNufaCTuReR suBmissioNs iN oNCology? Heemstra L. , Sweeney N. , Van Engen A. Quintiles, Hoofddorp, The Netherlands objeCtives: Evidence Review Groups (ERGs) provide a critical appraisal of the manufacturer submission in the NICE single technology appraisal (STA) process. As the academic centres may differ in experience and methodology, the objective of this study was to evaluate whether the focus areas and key criticisms differ between ERGs. Methods: The NICE website was searched for all NICE oncology STAs, published between June 2010 and June 2013. The ERG reports were retrieved, and the main critiques were categorised for the five centres that performed the most evaluations. The focus areas of the ERGs were further studied. Results: A total of 27 STAs were identified with evaluations performed by 9 different ERGs. The most evaluations were performed by Liverpool (9), followed by Sheffield (4), and PenTAG, West Midlands and York (3 evaluations each). All ERGs would report uncertainties related to the extrapolation and gain in overall survival (OS), maturity of data, trial comparator, and the quality of life (QoL) data. In addition all critiques covered submission quality and disease specific challenges, yet variation was found in focus area between ERGs. For example a specific focus area of Liverpool was the OS modelling method. Proposed changes to survival modelling included separating the survival curves for pre-and post-progression, and removing any survival advantage post-progression where this was considered inappropriate. Comments from other agencies on OS were mainly limited to the choice of parametric survival function. Other areas that differed between ERGs were the systematic review methods (more often reported by Sheffield) and comments on the QoL data (York). ConClusions: Although all ERGs focus on uncertainty around the evidence and quality of the manufacturer submissions, the focus areas differed between the groups. The key difference seems to relate to research focus of the academic centre.
PCN209
Review of NiCe TeChNology aPPRaisals iN oNCology: how does CliNiCal evideNCe ChaNge oveR Time?
Dequen P. , Cooper N. J. , Abrams K. R.
University of Leicester, Leicester, UK
Drug licensing and reimbursement authorities worldwide are considering new ways to stimulate market access for innovative medicines such as accelerated approval and conditional coverage. Early release of pharmaceuticals calls for more responsive decision-making alongside continuous evidence generation throughout clinical development. We explore whether changing trends in clinical evidence considerations for health technology assessment (HTA) by the National Institute for Health and Care Excellence (NICE) may help inform future evidence requirements for rapid and early HTA. objeCtives: We investigate how the submission and acceptability of clinical evidence for single, multiple and repeated assessments of cancer drugs by NICE have changed in the past decade. Methods: We reviewed technology appraisals published online since February 2002 by NICE for pharmaceuticals in oncology. Information regarding the clinical evidence included and the methods used to analyse relative treatment effects across relevant comparators was extracted. Manufacturer submissions, assessment reports, and final appraisal determinations were considered for longitudinal comparison. Results: Out of a total of 254 appraisals identified since 2002, 85 assessed cancer drugs and 76 of these were included for review based on available documentation. Only 11 products had been re-assessed to date with initial guidance superseded by a multiple technology appraisal or clinical guideline. We found a greater reliance on phase II and observational data in recent appraisals, particularly for novel therapies in areas of high unmet need. Limited data was also accompanied by an increase use of surrogate outcomes and extrapolation of observed short-term clinical benefits. Recent submissions were also marked by the uptake of network meta-analysis methodologies. ConClusions: NICE has previously recommended cancer drugs based on immature clinical data allowing for considerable uncertainty in 'realworld' effectiveness estimates. However, these examples remain the exception to the rule; moreover our review highlighted a need for methodological development to deal with early clinical evidence.
PCN210 g-Ba assessmeNTs of oNCology TRials: is iNCReased oveRall suRvival a "musT have"?
Schuchardt M. 1 , Nijhuis T. 1 , Friedmann B. 2 1 Quintiles, Hoofddorp, The Netherlands, 2 Quintiles, Mannheim, Germany objeCtives: Objective of this research was to provide an overview of Health Technology Assessments (HTAs) in oncology after introduction of AMNOG in Germany. Methods: Quintiles' HTA database (HTA Watch) has been used to analyse HTAs in Germany. The timeframe chosen for analysis was 1st of January 2011 to 24th of June 2013. All reports have been analysed in detail to reveal key factors for success or failure, which are presented in the following. Results: Since introduction of AMNOG in 2011, thirty percent (13 out of 43) of all completed assessments by the G-BA (Federal Joint Committee) evaluated cancer drugs. The products assessed were abiraterone acetate, axitinib, brentuximab vedotin, cabazitaxel, crizotinib, decitabine, eribulin, ipilimumab, pixantrone, ruxolitinib, vandetanib, vemurafenib
